Research Alliance Corp. II (RACB): Price and Financial Metrics
GET POWR RATINGS... FREE!
RACB Stock Price Chart Interactive Chart >
RACB Price/Volume Stats
|Current price||$9.74||52-week high||$10.35|
|Prev. close||$9.76||52-week low||$9.64|
|Day high||$9.74||Avg. volume||80,667|
|50-day MA||$9.75||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||150.47M|
Research Alliance Corp. II (RACB) Company Bio
Research Alliance Corp. II intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry. The company was incorporated in 2020 and is based in Las Vegas, Nevada.
Most Popular Stories View All
RACB Latest News Stream
|Loading, please wait...|
RACB Latest Social Stream
View Full RACB Social Stream
Latest RACB News From Around the Web
Below are the latest news stories about Research Alliance Corp II that investors may wish to consider to help them evaluate RACB as an investment opportunity.
If you want to know who really controls Research Alliance Corp. II ( NASDAQ:RACB ), then you'll have to look at the...
Figure 1 Land Position Map VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Irving Resources Inc. (CSE:IRV; OTCQX: IRVRF) (“Irving” or the “Company”) is pleased to provide an update of exploration work at its 100% controlled Omu epithermal gold-silver vein project, Hokkaido as well as its Newmont alliance projects elsewhere in Japan. Summary of Work at Omu Epithermal Gold-Silver Vein Project Since initiating its 2021 diamond drilling program beginning in March, Irving has completed three diamond drill holes, 21OMS-001, 21OMS-002 and 21OMS-003, at Omu Sinter target. A fourth hole, 21OMS-004, is currently in progress and nearing its targeted depth. Holes 21OMS-001 and 21OMS-003 tested two new zones of high resistivity, the first to the west and the second to the east of the m...
POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.
RACB Price Returns